Somerset TherapeuticsdrugHigh PriorityActive

Cisatracurium Besylate Recall

Cisatracurium Besylate Injection 10 mg/5 mL* (2... has been recalled due to subpotent product:out of specification assay results observed during long term stability testing.. This recall primarily affects healthcare facilities, hospitals, and pharmacies. Individual consumers are unlikely to have this product at home. Check the official FDA notice for specific lot numbers and return or disposal instructions.

By RecallRadar Editorial Team

Sourced from FDA. Last verified March 4, 2026.

On this page

Free checker

Check if you qualify

See whether your device may qualify for a free repair or replacement program before you spend money.

Check if you qualify

Key facts

Date announced
November 26, 2025
Source agency
FDA

This recall involves safety concerns. Take action promptly.

✨ Plain-English Summary

Cisatracurium Besylate Injection 10 mg/5 mL* (2... has been recalled due to subpotent product:out of specification assay results observed during long term stability testing.. This recall primarily affects healthcare facilities, hospitals, and pharmacies. Individual consumers are unlikely to have this product at home. Check the official FDA notice for specific lot numbers and return or disposal instructions.

Is This Recall Still Active?

Status: Yes - Active

This recall is currently active. If your device matches the affected models, follow the official instructions as soon as possible.

What's Being Recalled

Quoted source excerpt from the official notice.

Subpotent product:out of specification assay results observed during long term stability testing.

Quick Info

Key facts from the official notice, kept in the article flow for easy cross-checking.

Brand
Somerset therapeutics
Category
drug
Source agency
FDA
Announced
November 26, 2025
Country
US
Status
Active

Who's Affected

Specific models and identifiers listed in the source notice:

Model #1

Lot#: A240438, Exp Date 1/31/26, A250125, Exp Date 8/31/26

Technical model codes are manufacturer identifiers. Match both the product name and model code from your device settings, label, or packaging.

What You Should Do

Follow the remedy path from the official notice using the exact model and serial details above.

  1. 1## Cisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single-dose 5 mL vial NDC 70069-141-01; 10x5 mL single dose vial Agency: FDA | Category: drug Reason: Subpotent product:out of specification assay results observed during long term stability testing. What to do:
  2. 2Stop using the product if your lot/model matches.
  3. 3Check the FDA notice for specifics.
  4. 4Follow remedy instructions.
Open Official Recall Notice

Source & Verification

This page summarizes the official notice and keeps key facts easy to verify.

Official source
FDA
Announced by source
November 26, 2025
Last reviewed by RecallRadar
March 4, 2026

Frequently Asked Questions

Am I affected by this recall?

Check the affected models section on this page. The official notice currently lists Lot#: A240438, Exp Date 1/31/26, A250125, Exp Date 8/31/26.

What is the remedy for this recall?

## Cisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single-dose 5 mL vial NDC 70069-141-01; 10x5 mL single dose vial Agency: FDA | Category: drug Reason: Subpotent product:out of specification assay results observed during long term stability testing. What to do: 1. Stop using the product if your lot/model matches. 2. Check the FDA notice for specifics. 3. Follow remedy instructions.

Where can I verify recall details?

Use the official source link in this page to confirm dates, eligibility, and next steps: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts

Keep browsing with these internal hubs: Somerset Therapeutics recall hub and Food & Drug recall hub.

Official Resources

Use these primary sources for final eligibility and claim instructions.

View official notice from FDA

See an inaccuracy?

Help us improve the accuracy of this recall information.

500 characters remaining

Related Recalls

Amazon basic care acetaminophen
Medium PriorityActive

amazon, Acetaminophen, Extra Strength, 500mg Caplets, 1000-count bottle, Distributed by: Amazon.com Services LLC, 410 Terry Avenue N., Seattle, WA 98109, Made in India, NDC 72288-692-01. UPC 1 95515 04888 0

Discoloration: consumer complaints received for discolored tablets

Oct 7, 2026

Paroxetine hydrochloride
High PriorityActive

Paroxetine Extended-Release Tablets, 37.5mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-1318-3

Failed dissolution specifications.

Oct 7, 2026

Focus pi
High PriorityActive

FOCUS PI Hypromellose 0.7% Formula, 0.3 FL O (10 mL) per vial, STERILE, Manufactured for: Covalent Management, Inc., Manassas, VA 20109. NDC: 82724-007-19

Lack of Assurance of Sterility

Oct 7, 2026

Zoladex
High PriorityActive

Zoladex (goserelin) implant, 3.6 mg, One single-Use Syringe packaged in a carton, Rx only, Manufactured for: TerSera therapeutics LLC, Deerfield, IL 60015, BY: AstraZeneca UK Limited, Macclesfield, England, Product of Switzerland, website at www.zoladex.com, NDC 70720-950-36.

Temperature Abuse: Product sat in a non-temperature-controlled FedEx trailer at ambient outdoor conditions for 25.5 hours.

Oct 7, 2026

Buprenorphine hydrochloride
High PriorityActive

Buprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: Endo USA, Malvern, PA, NDC 42023-179-05

Crystallization

Oct 7, 2026